Complete response of esophageal small cell carcinoma amrubicin treatment

2013 ◽  
Vol 19 (4) ◽  
pp. 770-775 ◽  
Author(s):  
Eijiro Nagasaki ◽  
Masami Yuda ◽  
Yuichiro Tanishima ◽  
Yasuhiro Arakawa ◽  
Kazuma Kobayashi ◽  
...  
2020 ◽  
Vol 13 (1) ◽  
pp. 373-378 ◽  
Author(s):  
Yuri Nakao ◽  
Satoshi Tamauchi ◽  
Nobuhisa Yoshikawa ◽  
Shiro Suzuki ◽  
Hiroaki Kajiyama ◽  
...  

We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outcome. The patient was a 62-year-old woman with a chief complaint of irregular vaginal bleeding. Magnetic resonance imaging showed a 10-cm irregular mass from the uterine corpus’s posterior wall to the cervix. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node sampling were performed for suspected uterine sarcoma. Histopathological findings revealed small cell carcinoma with lymph node metastasis. Although 6 cycles of etoposide + cisplatin were performed, para-aortic lymph node recurrence was found 3 months after chemotherapy. Subsequently, the patient received 8 cycles of TC + Bev, which eliminated the metastases. The patient is currently alive at 24 months.


2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Rafael Oliveira ◽  
Mayra Coelho Bócoli ◽  
João Carlos Saldanha ◽  
Eddie Fernando Candido Murta ◽  
Rosekeila Simões Nomelini

The primary small cell carcinoma of the vagina is rare, and it is a highly aggressive malignancy with no consensus regarding the treatment of this tumor. The survival rate for patients treated in the early stages is around two years. We related the case report of a patient of 41 years with a vegetative and necrotic lesion in left vaginal wall, in middle and upper third, and involvement of parametrium in its proximal third and medium third. A biopsy showed a small cell undifferentiated carcinoma composed of epithelial cells with round nuclei, oval or elongated, hyperchromatic nuclei, with little distinct nucleoli, and scarce cytoplasm. Immunohistochemistry showed positivity for AE1/AE3, CD57, and chromogranin A. The patient received 6 cycles of chemotherapy with cisplatin and etoposide and radiotherapy, achieving complete response, with complete regression of the lesion. The patient had no sign of tumor recurrence and locoregional or distant metastases after 5 months of followup.


1994 ◽  
Vol 4 (2) ◽  
pp. 127-130 ◽  
Author(s):  
R. W. Hunter ◽  
M. Buck ◽  
I. G. Hammond ◽  
K. E. Williams

A 54-year-old woman with inoperable metastatic small cell carcinoma (SCC) of the endometrium was treated with cisplatin and etoposide chemotherapy on the basis of the histologic similarity to pulmonary SCC. The response to treatment was monitored using serum neuron specific enolase (NSE) levels. A complete remission was obtained with resolution of symptoms and disappearance of the mass. The patient is alive and well 4½ years later. Considering the aggressive behavior and short survival usually associated with this tumor and the presence of such advanced disease, a complete response to chemotherapy was unexpected. It would appear that chemotherapy should always be considered in the management of metastatic endometrial SCC, even in the presence of large-volume disease.


1985 ◽  
Vol 3 (7) ◽  
pp. 969-976 ◽  
Author(s):  
L H Maurer ◽  
T Pajak ◽  
W Eaton ◽  
R Comis ◽  
P Chahinian ◽  
...  

Patients with limited-stage small-cell carcinoma of the lung (SCCL) were randomly assigned to a four-drug chemotherapy program consisting of methotrexate, doxorubicin, cyclophosphamide, and CCNU (MACC) or to a regimen consisting of cyclophosphamide, CCNU, and vincristine alternated with Adriamycin (Adria Laboratories, Columbus, Ohio) and vincristine (CCV/AV). All patients received 4,500 cGy, in a split course, to the primary tumor, mediastinum, and supraclavicular lymph node drainage areas and 3,000 cGy to the whole brain. After four cycles of chemotherapy, patients were randomly assigned to chemotherapy plus methanol extractable residue of BCG (MER-BCG) or no MER-BCG. The complete response frequencies were similar for the two regimens (54% and 48%) as were the median survivals (12.0 and 11.5 months) and the two-year survival rates (15% and 17%). Immunotherapy with MER-BCG did not prolong the time to disease progression or improve survival. Women had a greater chance of achieving a complete remission independent of performance status. There was a complex interaction between sex and the chemotherapy regimens that may have important implications for the design and stratification of future trials in SCCL.


1983 ◽  
Vol 28 (3) ◽  
pp. 248-254
Author(s):  
W. MacNee ◽  
D. Maloney ◽  
D. Lamb ◽  
M. F. Sudlow

Thirty-seven consecutive patients, referred to a respiratory unit with a histological diagnosis of small cell carcinoma of the bronchus, were treated with a combined chemotherapy regime of adriamycin, vincristine and cyclophosphamide. Palliative radiotherapy was given for the control of symptoms. Thirty of 37 patients responded to treatment, 11/37 having a complete and 19/37 a partial response. The median survival of those patients with a complete response was 55 weeks, significantly higher (P<0.01) than either those with partial or no response to treatment. Those patients with limited disease survived longer. A high proportion of patients relapsed at the primary site of the tumour in the lungs. The relationship between the therapeutic response and the histological subtype of small cell carcinoma suffered from the limitations of the available pathological material. However, more of the patients with a complete response were of the lymphocytic-like pattern of small cell carcinoma. Useful survival in these patients with inoperable small cell carcinoma was achieved using this regime of chemotherapy, even in those patients with extensive disease, five of whom had survived for over one year.


1984 ◽  
Vol 2 (4) ◽  
pp. 294-304 ◽  
Author(s):  
R Feld ◽  
W K Evans ◽  
G DeBoer ◽  
I C Quirt ◽  
F A Shepherd ◽  
...  

One hundred fifty-three patients with limited and 167 with extensive small cell carcinoma of the lung (SCCL) were evaluable for response to treatment with six courses of chemotherapy (cyclophosphamide, doxorubicin, and vincristine), irradiation to intrathoracic disease, and prophylactic cranial irradiation (PCI). No maintenance chemotherapy was given. Fifty-two percent of patients with limited disease (LD) and 10% of extensive disease patients (ED) achieved a complete response. The median survival times for LD and ED patients were 49 and 34 weeks, respectively. These results were compared to a previous experience with 147 patients who were treated with three courses of similar induction chemotherapy and thoracic irradiation, as well as one year of maintenance chemotherapy (CCNU, procarbazine, and methotrexate) but without PCI. Although the use of PCI was found to reduce the frequency of brain metastases as the site of first relapse, detailed comparisons of response rates and survival showed no significant differences between the two study populations. Prolonged maintenance chemotherapy of the type used in the first study does not favorably influence outcome after intensive induction therapy for SCCL.


Sign in / Sign up

Export Citation Format

Share Document